• Profile

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomized, controlled, open-label, platform trial

The Lancet Feb 15, 2022

In this study, use of casirivimab and imdevimab (monoclonal antibodies) in combination in patients hospitalized for COVID-19 led to decrease in 28-day mortality in those who were seronegative (and thus had not mounted their own humoral immune response) at baseline but not in those who were seropositive at baseline.

  • In this randomized, controlled, open-label platform trial (RECOVERY), patients aged at least 12 years admitted to hospital with clinically suspected or laboratory-confirmed SARS-CoV-2 infection were included.

  • A total of 4,839 patients were randomized to casirivimab and imdevimab plus usual care and 4946 to usual care alone.

  • In the primary efficacy population of seronegative patients, death within 28 days occurred of 24% of patients who received casirivimab and imdevimab vs 30% of patients allocated to usual care (rate ratio [RR] 0·79).

  • In an analysis of all randomly assigned patients (regardless of baseline antibody status), 19% of patients treated with casirivimab and imdevimab vs 21% of patients allocated to usual care died within 28 days (RR 0·94).

  • The proportional impact of casirivimab and imdevimab on death varied significantly between seropositive and seronegative patients.

  • No treatment related deaths occurred, and no meaningful between-group differences existed in the pre-specified safety outcomes of cause-specific mortality, cardiac arrhythmia, thrombosis, or major bleeding events.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen